Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion type Assertion NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_head.
- NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion description "[Thus, we have shown that rosiglitazone appears to have direct anti-atherosclerotic effects in an animal model of diabetes-associated atherosclerosis which are at least partly due to effects on VCAM-1, ICAM-1, MCP-1 and P-selectin expression which leads to decreased leukocyte adhesion and macrophage infiltration.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_provenance.
- NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion evidence source_evidence_literature NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_provenance.
- NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion SIO_000772 18093596 NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_provenance.
- NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion wasDerivedFrom befree-2016 NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_provenance.
- NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_assertion wasGeneratedBy ECO_0000203 NP646272.RA1g5mE1CjCJ3b56ldZYXUehhRlxL23b6Pc47qwiWY0x8130_provenance.